Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;16(2):210-4.
doi: 10.4103/0973-029X.98893.

Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review

Br Varun  1 , Tt Sivakumar, Bindu J Nair, Anna P Joseph
Affiliations

Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review

Br Varun et al. J Oral Maxillofac Pathol. 2012 May.

Abstract

Background: Bisphosphonate therapy is widely used for the treatment of bone metastasis in breast cancer patients.

Aim: The aim of this study is to estimate the overall prevalence of bisphosphonate induced osteonecrosis of jaw (BONJ) in breast cancer patients with bone metastasis.

Materials and methods: A literature review was conducted to search and evaluate all the articles that contained original data on the prevalence of BONJ in breast cancer patients from the year 2003-2009. Pubmed search terms used were bisphosphonate, osteonecrosis, breast cancer and jaw. Eleven publications that fulfilled the inclusion criteria were chosen for the study. Case reports and reviews were excluded from the analysis based on assessing the title and abstract.

Results: Of the 2490 breast cancer patients, 69 developed BONJ with the overall prevalence rate of 2.8%. All the patients with BONJ had received zoledronate or pamidronate, either alone or in combinations.

Conclusion: BONJ is a significant complication occurring in 2.8% of the breast cancer patients receiving bisphosphonates for metastatic bone disease. It is very important to identify the trigger factors associated with BONJ and also to establish guidelines for the prevention and effective treatment of this condition.

Keywords: Bisphosphonate; breast; cancer; osteonecrosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433–41. - PubMed
    1. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–34. - PubMed
    1. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasis: Long tern follow up of two randomized placebo controlled trials. Cancer. 2000;88:1082–90. - PubMed
    1. Jagdev SP, Purohito P, Heatley S, Herling C, Coleman RE. Comparison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12:1433–38. - PubMed
    1. Marx RE. Pamidronate and zoledronate induced avascular necrosis of jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–17. - PubMed